Investors Face Losses in PROCEPT BioRobotics Securities Lawsuit

The lawsuit, spearheaded by Robbins LLP, claims that PROCEPT incentivized bulk orders to artificially boost handpiece unit sales, creating a massive inventory glut. By pulling forward sales, the company allegedly misled the market regarding actual procedure demand. This practice resulted in more than 10,000 excess units in the field by the end of the class period, according to the complaint.

Market confidence began to erode in August 2025 when the company reported deteriorating shipments, followed by a series of downward revisions to sales guidance. The situation culminated on February 25, 2026, when PROCEPT finally disclosed the disparity between units sold and actual medical procedures performed. Following this revelation, the company’s stock price dropped from $27.84 to $22.69 over two trading days, continuing a downward trend that pushed shares below $18 by July 2026.

Investors who incurred losses during the designated period may participate in the litigation without upfront costs, as the firm operates on a contingency fee basis. Those interested in the recovery process should contact attorney Aaron Dumas, Jr. to discuss their legal standing before the court-mandated deadline.